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INTRODUCTION 
Tacrolimus (formerly known as FK506) is a macrolide antibiotic isolated from the soil fungus Strtptomyus tsukubamsis. 1 Although it is totally dis-
tinct in molecular structure from cyclosporine A (CsA), a cyclic endecapeptide 
extracted from the fungus Tolypociadium inflatum, the two immunosuppres-
sants share a remarkably similar, selective inhibitory action on the activation 
and proliferation of CD4> T helper (TH) lymphocytesz.6 (see also chapter 10.3). 
In 1989, the first account of the ability of tacrolimus to prevent or reverse 
human organ allograft rejection was publishedJ Data obtained over the ensu-
ing 5 years have provided good evidence that tacrolimus is at least as valuable 
an investigational tool and clinical immunosuppressive agent as CsA. 8.9 Multi-
center, prospective. randomized controlled trials of tacrolimus versus CsA in 
primary liver transplantation have shown significantly reduced rates of acute 
rejection and reduced steroid requirements in the tacrolimus arm of the trials. 
In April 1994, tacrolimus was approved by the US Food and Drug Adminis-
tration for the therapy of liver allograft rejection. Whilst the potential ben-
efits of tacrolimus in organ transplantation are now widely recognized. the 
prospective value of the drug in the treatment of autoimmune disorders is 
now also being assessed. In this chapter. we discuss the rationale for the use 
of tacrolimus in autoimmune disease. and report on the early clinical experi-
ence with the drug in the management of a variety of autoimmune diseases 
conducted principally at the University of Pittsburgh Medical Center (UPMC) 
(Table 10.8.1). 
RATIONALE FOR THE USE OF TACROLIMUS IN 
AUTOIMMUNE DISEASES 
The therapeutic use of tacrolimus in a particular autoimmune disease is 
based on the premise that the disorder is T cell driven. lO In autoimmune uveitis,11 
type I diabetes. 12 multiple sclerosis, IJ psoriasis. 14 and rheumatoid arthritis for 
example, T cells are believed to play an important pathogenic role. Much of 
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the evidence to support this view comes from stud-
ies in experimental animals and from investigations 
in vitro of the adverse or destructive interactions 
between T cells, antigen-stimulated T cell-derived 
cytokines and the target tissue affected by the dis-
ease process. In the autoimmune liver diseases,Is 
chronic active hepatitis (CAH), primary biliary cir-
rhosis (PBC) and in rheumatoid arthritis,I6 there is 
abundant evidence for the involvement of T cells in 
the pathogenesis of each disease and therefore a ra-
tionale for the use of tacrolimus in each exists. In 
recent years, the therapeutic efficacy of CsA in sight-
threatening uveitis, severe psoriasis, PBC, CAH and 
rheumatoid arthritis has been demonstrated. I7 More-
over, CsA has been shown to alter the natural his-
tory of recent onset type-I diabetes. IS Notably how-
ever, CsA has not made a significant impact upon 
the clinical management of patients with most of these 
diseases. 
In autoimmune diseases such as systemic lupus 
erythematosus (SLE), or the nephrotic syndrome, the 
rationale for the use of CsA or tacrolimus is less clear. 
Thus in SLE, humoral immunity appears to be more 
important than cellular immunity in the pathogen-
esis of the disease, while in idiopathic nephrotic syn-
Table 1O.B.l. Protocols for treatment of autoimmune 
diseases utilizing tacrolimus at the University of 
Pittsburgh Medical Center 
Eye and ear diseases 
Uveitis; scleritis 
Ocular cicatrical pemphigoid 
Autoimmune inner ear disease 
Neurologic 
Multiple sclerosis; amyotrophic lateral sclerosis 
Renal 
Nephrotic syndrome 
Gastrointestinal 
Ulcerative colitis 
Crohn's disease 
Chronic active hepatitis (autoimmune) 
Primary sclerosing cholangitis 
Primary biliary Cirrhosis 
Celiac sprue 
Skin 
Psoriasis 
Pyoderma gangrenosum 
Epidermolysis bullosum 
AlopeCia universalis 
Endocrine 
New onset type I diabetes 
Collagen vascular disease/vasculitis 
Behcet's disease 
Scleroderma 
Rheumatoid arthritis 
Polymvositis/dermatomyositis 
Wegeners granulomatosis 
drome, the pathogenic mechanisms are far from clear. 
Nevertheless, T cell dysfunction, recruitment of B-
lymphocytes and immunoglobulin deposition within 
the kidney and a central role for lymphokines in 
nephrotic syndrome have been implicated by various 
authors. I9-22 In addition, CsA has been shown to be 
very effective in steroid-sensitive nephrotic syndrome, 
although less so in steroid-resistant patients. 17 
The predicted efficacy of tacrolimus in a particular 
human autoimmune disorder is based on the assump-
tion that the role of T cells is central to the disease 
process. It is also based on experience in animal models 
of these diseases treated with either CsA or tacrolimus 
(see chapter 10.3). Account is also taken of previous 
clinical experience with CsA in these diseases. 
COMPARATIVE BIOLOGICAL AND 
PHARMACOLOGICAL PROPERTIES OF 
TACROLIMUS AND CsA 
Although distinct in molecular structure, tacrolimus 
and CsA share many biological and pharmacological 
properties (e.g .• binding to intracellular immunophilins, 
selective interference with CD4+ T cell function, rate 
of systemic absorption, plasma half-lives, etc.). These 
similar properties of the two immunosuppressants are 
Table IO.B.2. Biological and pharmacological 
properties of 
tacrolimus and CsA 
Similarities 
- Molecular action and antilymphocytic activity (similar 
actions on CD4+ T cells and cytokine generation) 
- Interfere with T cell maturation (reversible) 
- Immunosuppressive and toxic effects related 
mechanistically 
- Inhibition of mast cell degranulation 
- Bind to intracellular immunophilin (CsA to cyclophilin; 
tacrolimus to FKBP) 
- Inhibition of apoptosis 
- Absorbed orally 
- Metabolized in liver (cyt P4S0 mixed function oxidases) 
- Metabolites are excreted into bile 
- Wide tissue distribution (lipophilic) 
- pfasma 1/2 lives (CsA S-12hr; tacrolimus 4-14hr) 
- Absorption (CsA 24 hr; tacrolimus 1/2-4hr) 
- Not excreted in urine « 2')10) 
- Metabolites ineffective 
- Oral absorption (CsA 30%; tacrohmus 35%) 
- Drug interactions (e.g. erythromycin; ketoconazole) 
- Hepatotrophic 
- Predominant blood distribution In RBC 
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listed in Table 10.8.2. Properties of tacrolimus and 
CsA which are known to differ are shown in Table 
10.8.3. Of special significance, in relation to the 
potential value of the drugs in autoimmune diseases, 
is the superior capacity of tacrolimus, compared with 
CsA, to reverse cell-mediated immunity (e.g., allograft 
rejection or graft-versus-host disease). 
INFLUENCE OF TACROLIMUS ON 
EXPERIMENTAL AUTOIMMUNE 
DISEASES 
Tacrolimus is effective in inhibiting a wide vari-
ety of experimental autoimmune disorders in rodents 
and in larger laboratory animals (see pr~vious chap-
Table 10.B.3. Biological and pharmacological 
properties of tacroJimus and CsA 
Differences 
- Molecular structure 
- Immunophilins distinct 
- Therapeutic level ((sA !1g ml; Tacrolimus: ngiml) 
- (sA absorption (but not that of Tacrolimus) dependent on 
bile flow 
- Tacrolimus (but not (sA) reverses cell mediated immunity 
(GVHD, allograft rejection) 
- Drug interactions-no change of Tacrolimus level with the 
combination of calcium channel blockers 
- Hypogonadism (male especially 
& femaleH(sA) 
- Antilymphocytic effects of Tacrolimus less easily reversed 
(in vitro) 
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ter). The autoimmune diseases in which the immu-
nosuppressive efficacy of tacrolimus has been proven 
include uveitis, type-I diabetes, thyroiditis. autoim-
mune renal disorders, experimental allergic encephalo-
myelitis (a correlate of multiple sclerosis) and autoim-
mune myocarditis. An example of the inhibitory effect 
of tacrolimus on experimental autoimmune disease 
is shown in Figure 10.8.1. PVG/c female rats which 
have been neonatally thymectomized and sublethally 
irradiated subsequently develop autoimmune thy-
roiditis. The development of the disease is inhibited 
by a 3-week course of systemic tacrolimus starting 
after demonstration of serological evidence of autoan-
tibody (anti-thyroglobulin antibody) production.23 
Some untreated disease control animals also develop 
insulitis. This is also prevented by tacrolimus admin-
istration. 
EARLY CLINICAL EXPERIENCE WITH 
TACROLIMUS AT THE UNIVERSITY OF 
PITTSBURGH MEDICAL CENTER 
PRIMARY SCLEROSING CHOLANGITIS (PSC) 
A total of 11 cases of primary sclerosing cholangitis 
(PSC) have been treated with tacrolimus in the au-
toimmune clinic at UPMC. Most of these cases have 
also had ulcerative colitis. A few have either had 
Crohn's colitis (n = 4) or no colonic disease at all 
(n = 4). The biochemical responses of a representa-
tive responder with PSC and ulcerative colitis to 
tacrolimus therapy is shown in Figure 10.8.2. A 
dramatic decline in total bilirubin and alkaline phos-
phatase occurred early, with a later reduction in the 
AL T and AST levels. 
EFFECT OF FK506 ON THE SEVERITY 
OF THYROIDITIS 
Fig. 7 O.B.1. Inhibitory efiect of tacrolimus (FK506) on 
experimental autoimmune thyroiditis. For further de· 
tails see Tamura et aU] 
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Fig. 10.8.2. Biochemical 
responses (serum total bi-
lirubin, alkaline phos-
phatase, AL T and AST lev-
els) in a representative re-
sponder with PSC treated 
with tacrolimus (FK506). 
Reproduced from /hanson 
AW et a/. Springer Semin 
Immunopathol 1993; 14: 
323-344. 
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Sixteen patients with PBC have been treated with 
tacrolimus in the autoimmune clinic of UPMC. The 
majority of these cases have been women. Most but 
not all have shown a response to tacrolimus therapy, 
as illustrated in Figure 10.8.3, with a marked reduc-
tion in the serum bilirubin and alkaline phosphatase 
levels and with modest reductions into the normal 
range for serum AL T and AST levels. 
AUTOIMMUNE CHRONIC ACTIVE HEPATITIS 
(CAH-A) 
Twenty one cases of autoimmune CAH have been 
treated with tacrolimus at UPMC. The majority have 
been women. Half had failed to respond to gluco-
corticoids alone or used in combination with aza-
thioprine. One failed with CsA. Elevated bilirubin 
and transaminase levels declined into the normal range 
with the institution of tacrolimus (Fig. 10.8.4). Of 
the three hepatic diseases that have been treated with 
tacrolimus, this group with autoimmune CAH ap-
pears to respond best and most consistently. 
CROHN'S DISEASE 
A total of 17 patients with Crohn's disease have 
been treated with tacrolimus at UPMC. Most have 
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had complicated diseases, involving the colon or co-
lon and small bowel with multiple perianal, vaginal, 
vesicular or cutaneous fistulae. Tacrolimus treatment 
has, in all cases, been followed by a reduction in the 
amount of drainage and in most cases, by drying up 
of fistulous tracts. Enteric disease has not been eradi-
cated with tacrolimus, however its use has allowed 
complications of Crohn's disease to resolve such that 
surgical repair has become possible in some cases. A 
beneficial use of tacrolimus in this disease process 
may therefore be in the preoperative management of 
cases. In individual subjects, an apparently inoper-
able case could be converted to an easily resectable 
one with the use of tacrolimus. Moreover, it:; use 
preoperatively may enable the patient to go to sur-
gery without the use of steroids that complicate healing 
and foster infection in the early postoperative period. 
ULCERATIVE COLITIS 
Nineteen cases of ulcerative colitis have been 
treated with tacrolimus. Eleven patients also have PSC, 
while 6 do not have confounding PSc. A clear re-
sponse of the symptoms or the underlying pathology 
to tacrolimus treatment has not been noted; how-
ever treatment has enabled several of the patients 
without PSC to stabilize their disease activity and 
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undergo surgery to treat a complication of the dis-
ease, usually a colonic stricture. The role of tacroli-
mus in the management of ulcerative colitis appears 
to be less clear than in the treatment of Crohn's dis-
ease and its complications. 
SPRUE (CELIAC DISEASE) 
Four patients with sprue documented by (1) the 
presence of gluten sensitivity (2) an atrophic small 
bowel mucosa on intestinal biopsy and (3) the pres-
ence of detectable reticulum antibodies have been 
treated with tacrolimus. One of these 4 cases had 
failed gluten withdrawal and had required total 
parenteral nutrition (TPN) for several years prior to 
[he use of tacrolimus. Three patients are able to eat 
.1 normal diet containing gluten without the devel-
opment of symptoms while taking [acrolimus. D-xy-
lose absorption has improved in all 4 subjects, but 
remains abnormal in the single patient who had re-
quired TPN for several years prior to the institution 
of tacrolimus. On tacrolimus, the appearance of in-
testinal biopsies improved in all cases. The improve-
ment has been rather small however. in the single 
(ase that had required TPN to maintain her nurri-
tional status prior to the use of tacrolimus. ~ euro-
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Fig. 10.8.3. Biochemical 
responses (serum total bi· 
lirubin, alkaline phos· 
phatase, AL T and AST lev· 
e/s) in a represl?ntative re-
sponder with PBC treated 
with tacrolimus (FK506). 
Reproduced from lhanson 
AW et a/. Springer Semin 
Immunopathol 1993; 14: 
323·344. 
toxicity limited increasing the dose of tacrolimus in 
this patient whose levels remained in the low thera-
peutic range during treatment. Nonetheless, the 
extraintestinal consequences of her disease, hypo-
gonadism. cheilitis. hair loss. fatigue and seizures re-
lated to hypocalcemia resolved or improved while on 
tacrolimus. 
UVEITIS/SCLERITIS (N = 3) 
Tacrolimus appears to be of benefit in these con-
ditions. Z4 One patient with scleritis who was refrac-
tory to CsA has responded to tacrolimus. Prelimi-
nary data appear to show that steroid use will still 
be required in these conditions. although at a reduced 
dose. Mochizuki and his colleagues (Kurume Uni-
versity School of Medicine. Fukuoka, Japan) have re-
ported on the efficacy of tacrolimus in refractory uveitis 
in 8 patients, 5 with Behcet's disease and 3 with 
idiopathic retinal vasculitisK~F The mean observation 
period was 22 weeks. Seven of the cases had no side 
effects; 1 patient developed moderate renal impair-
ment. The effects of tacrolimus by the criteria of 
improved visual acuity and uveitis activity were dose 
dependent. In most cases. 0.15 :lnd C.2 mg/kg/day 
were dfective. 
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Fig. 10.8.4. Biochemical 
responses (serum total bi-
lirubin, alkaline phos-
phatase, AL T and AST lev-
els) in a representative 
responder with CAH-A 
treated with tacrolimus 
(FK506). Reproduced 
from lhanson AW et al. 
Springer Semin lmmuno-
pathol1993; 14:323-344. 
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The results of treatment of psoriasis with tacroli-
mus (n = 16) have been quite rewarding. ZG All pa-
tients have shown a dramatic response to treatment-
some with rapid clearing. while others take months 
to show clearing of the disease. Disease remission is 
associated with reductions in activated T cells.27 se-
lective inhibition of cytokine gene expression28 .29 and 
reduced adhesion molecule expression. 30 The renal 
toxicity of the drug appears to limit the ability to 
achieve remissions in some patients. especially in those 
who have received prior treatment with methotrexate. 
Combination therapy may be required in some of 
these subjects, and may limit the toxicities of single 
agents used in comparatively large doses. 
PYODERMA GANGRENOSUM 
The results of treatment of pyoderma gangrenosum 
(n = 6) with tacrolimus are promising. 3I.32 One pa-
tient who was chronically steroid-dependent since 
childhood, with multiple steroid-induced complica-
tions, was able to suspend the use of steroids for the 
first time in his life. Four out of 6 patients achieved 
total remissions and 1 significant partial remission 
was obtained. One patient who did not respond to 
CAH-A 
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CsA was also refractory to tacrolimus and interest-
ingly. showed in vitro evidence of lymphocyte resis-
tance to the drug up to 100 ng/ ml. 
MULTIPLE SCLEROSIS 
More than 100 patients with chronic progressive 
multiple sclerosis (MS) have been treated beyond 1 
year with tacrolimus in a 3 year protocol. Patients 
with both severe and mild disabilities have been treated. 
so the group is heterogenous. Some patients who 
received tacrolimus for transplants and who coinci-
dentally, had MS, appear to have shown objective 
improvements over time. The neurotoxicity of the 
drug may be more limiting in this condition than in 
other autoimmune disorders. Although it is too early 
in the course of treatment to assess the effect of tacro-
limus on disease progression, the side effects of 
tacrolimus were mild and the overall degree of 
disablility did not deteriorate significantly in 1') pa-
tients studied over 12 monthsY 
NEW ONSET TYPE-I DIABETES MELLITUS 
A pilot study examined the capacity of tactolimus 
to induce complete remission in new onset type I 
diabetes. Thirteen patients aged 23.5 ± 2.8 years with 
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duration of diabetes symptoms 19.1 ± 2.4 days, weight 
loss 5.9 ± 1.1 % and insulin treatment 6.2 ±1.2 days 
were treated with oral tacrolimus (0.3 mg/kg/day). All 
patients had ketonuria but only 1 had mild ketoacidosis 
(HC0 3 < 18) at presentation. Four (31 %) had 
noninsulin requiring remission at 4-6 months on 
tacrolimus treatment. Every patient with remission 
had stimulated C-peptide > 0.6 pmol/ml. This was 
not predictive since some patients with this level of 
C-peptide did not have remission. Only 1 patient 
with remission had a non-diabetic oral glucose toler-
ance test on tacrolimus. Remission was very short-lived 
« 4 months) with no precipitating event or loss of 
C-peptide to explain recurrent hyperglycemia. There 
was no improvement of glycemia or reduction of 
insulin dose when tacrolimus was decreased. When 
the drug was discontinued, some patients lost C-pep-
tide. Subjective side effects included headache and 
muscle cramps. There also were reversible, dose-re-
lated rises in serum creatinine, hyperkalemia and 
hypertension. Since in contrast to previously reported 
studies on CsA, tacrolimus did not induce long term 
remission in new onset type I diabetes, this may imply 
that in patients with a low p-cell mass, the drug is 
more diabetogenic than CsA. Low dose tacrolimus 
that can minimize toxicity can preserve C-peptide 
secretion. 
NEPHROTIC SYNDROME 
Experience in treating steroid-resistant nephrotic 
syndrome (n = 32) with tacrolimus monotherapy has 
demonstrated three distinct patterns. }4.35 The three 
groups are approximately equally divided. Some pa-
tients experience a rapid reduction in proteinuria to 
normal or near normal values within weeks of initi-
ating therapy. Others respond partially to tacrolimus 
alone, with reduction of protein excretion to approxi-
mately 50% of pretreatment values. The third group 
has demonstrated no change in protein excretion and 
has progressed to end stage kidney disease. The ma-
jority of patients treated to date have had focal scle-
rosing glomerulonephritis (FSGS) as the cause of ste-
roid-resistant nephrotic syndrome. This, and the other 
histologic lesions treated in the study, tend to be 
resistant to essentially all forms of therapy and tend 
to progress to end stage renal disease. Partial and rotal 
unresponsiveness to tacrolimus may reflect that me-
diation of FSGS and other glome;ulopathologies in 
(hese patients lies distal to IL-2 activation. In these 
cases. addition of other immunosuppressive agents 
whic~ affect the more distal elements might improve 
(he erficacy of tacrolimus. The use of anti-B cell agents. 
such as cyclophosphamide in combination with 
tacrolimus (recently described in murine SLE. see 
previous chapter). would seem to be a rational choice. 
as would (he use of small doses of prednisone 111 
patients refractory to tacrolimus alone. 
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The nephrotoxicity of tacrolimus has been the 
primary limiting factor in the treatment of these dis-
eases. Like CsA, tacrolimus causes acute, dose-depen-
dent rises in serum creatinine. Renal function im-
proves with dosage reduction. The starting dose of 
tacrolimus has been reduced progressively from 
0.15 mg/kg/day, given twice, to approximately 1/3 
of this dose. Whether this approach will lessen the 
efficacy of tacrolimus is yet to be determined. No 
evidence of chronic tacrolimus toxicity has been ob-
served in any of the patients treated for nephrotic 
syndrome, even at the highest drug dose. 
SIDE EFFECTS OF TACROLIMUS IN 
HUMANS 
Side effects of tacrolimus and CsA observed both 
in transplant and autoimmune disease patients are 
shown in Table 10.8.4. Adverse effects associated with 
the use of tacrolimus in transplant patients have re-
cently been reviewed. 36 Adverse reactions requiring 
treatment or tacrolimus dose reduction are impair-
ment of renal function (due in part to decreased glom-
erular blood flow), alterations in glucose homeosta-
sis (a 15% incidence of new onset insulin-requiring 
diabetes has been observed in tacrolimus-treated trans-
plant patients but none in autoimmune disease pa-
tients treated with tacrolimus as a single agent) and 
Table 10.8.4. Potential side effects of tacrolimus and 
CsA in humans 
Similarities 
Decreased glomerular blood Now 
Elevated serum potassium (? reduced aldosterone sensitivity 
of renal tubules) 
De novo hypertension (CsA > tacrolimus) 
Lymphoproliferative disease' 
Nephrotoxicity 
Neurotoxicity 
Diabetogenicity 
Decreased bone mineralization "(in vitro) 
Steroid-sparing (tacrolimus > CsA) 
Differences 
Hirsutism (CsA; not tacrolimusl 
Gum hypertrophy (CsA; not tacrolimus) 
Hyperlipidemia (CsA) 
Hypocholesterolemla (tacrollnluS) 
Elevated 1.2S-(OHb D levels (CsA; not tacrolimus) 
• Reported In Ir,lnsplant patients 
•• Tacrolimus data based on In vllro observallons only 
Reproduced Irom Ihanson AW et .11. Springer Semln Immunopalhol 
1993; 1-1323-344 
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neurotoxIcity. Amongst the benefits of tacrolimus 
compared with CsA are a lower incidence of de novo 
hypertension and the absence of gum hypertrophy 
and hirsutism. The frequency of side effects noted 
in autoimmune patients is shown in Table 10.8.5. A 
1.6% incidence of posttransplant lymphoproliferative 
disorders has been observed in UPMC tacrolimus-
treated transplant patients. No lymphoproliferative 
disorders have been reported from the tacrolimus 
treated autoimmune disease patient population (mean 
follow up time> 36 months). 
AN INTELLIGENT DOSING SYSTEM FOR 
INDMDUALIZING TACROLIMUS 
THERAPY IN AUTOIMMUNE DISEASE 
The accuracy and precision of an intelligent dosing 
system (IDS) for tacrolimus in predicting doses to 
achieve target drug levels has been prospectively evalu-
ated both in transplant and autoimmune disease pa-
tientsY For dose individualization, the knowledge base 
is updated with patient-specific feedback, including 
the current dose, drug level and the new target level. 
The study population of 147 patients consisted of 
97 transplant patients (liver and kidney) and 50 pa-
tients with autoimmune disorders. Patients in the 
transplant study group were entered sequentially and 
followed as a cohort. Patients in the autoimmune study 
group were randomly assigned to one of three pre-
defined tacrolimus concentration windows (iow, 
0.1-0.3; medium, 0.4-0.7; and high, 0.8-1.3 ng/ ml) 
as part of a concentration-controlled clinical trial. 
Predictions of steady-state plasma drug levels were 
made throughout the clinical course of autoimmune 
disease patients and during the first 6 weeks post-
transplant in liver and kidney recipients. Tacrolimus 
concentration in plasma was measured by a mono-
clonal antibody-based ELISA assay. Accuracy was 
computed as the mean prediction error (mpe). Pre-
cision was computed as the root mean squared pre-
diction error (rmspe). The accuracy of the IDS in 
each study group was as follows: 0.016 ng/ml (liver), 
0.034 ng/ml (kidney), and -0.022 ng/ml (autoim-
mune). Because the 95% confidence interval included 
zero in each case, the IDS showed no bias. The pre-
cision of the IDS in each study group was as fol-
lows: 0.133 ng/mL (liver), 0.1903 ng/mL (kidney), 
and 0.1188 ng/mL (autoimmune). These results in-
dicate that the tacrolimus IDS is both accurate and 
very precise (reproducible) both in transplant and 
autoimmune patients. 
Table 10.8.5. Laboratory indices and side effeds in 64 tacrolimus·treated autoimmune 
disease patients (University of Pittsburgh Medical Center) 
(a) 
Parameter Baseline 3 Months 6 Months 
Serum creatinine (mg/dl) 0.95 ± 0.38 1.16±0.39 1.24 ± 0.44 
BUN (mgjdl) 13.0 ± 5.4 17.8 ± 6.6 20.3 ± 9.0 
Tacrolimus dose (mg/day) 8.5 ± 5.5 8.3 ± 5.6 7.8 ± 5.2 
Tacrolimus plasma level (ng/ml) 0.54 ± 0.31 0.62 ± 0.47 
Glucose (mg %) 106 ± 39 112±41 108 ± 38 
Hematocrit (%) 40 ± 6 37 ± 5 38 ± 5 
Potassium meqjl 4.2 ± 0.5 4.5 ± 0.4 4.4 ± 0.4 
Normal adult ranges: serum creatinine 0.5-1.4 mgjdl; BUN 5-20 mg/dl; glucose 65-115mg%; hematocrit 42·50%; 
potassium 65-115 meq/I. 
(b) 
Effect 
Need for anti-hypertensive medication (baseline 15.9%) 
Headache 
Insomnia 
Tremors 
Hyperesthesia 
Months After Treatment: 
Prevalence of Effect 
3 Months 6 Months 
25.4% 34.9% 
38.5% 37.5% 
33.3% 30.0% 
42.5% 42.5'Yo 
33.3% 30.0% 
Sixty-iour tacrolimus-treated autoimmune disease palients (age 39.7 ± 15.2 years; J2M:32F). 
Six months minimum iollow-up ior each patient. 
The primary disease was as iollows: AutOimmune Inner ear disease 3; Behcet's syndrome I; CAH-A 10: Corneal Tx 
(ophthalmology) 1; Diabetes type-I 5; EpidermolYSIS bullosa 1; Intlammatorv bowel disease 3; Multiple scleroSIS 20; 
Nephrotic syndrome 4; ScleritiS 1; PBC 5; PSC 2; PsoriasIs 5; Pyoderma gangrenosum I; Scleroderma 2. 
Tacrolimus and Therapy of Human Autoimmune Disorders 
PROSPECTS FOR DRUG COMBINATION 
THERAPIES 
In addition to tacrolimus monotherapy, the po-
tential exists for drug combination therapies in au-
toimmune disease using tacrolimus in combination 
with other novel or well-established classes of immu-
nosuppressive agents which act by mechanisms dif-
ferent from tacrolimus or CsA. Experimental combi-
nation therapies which are currently envisaged (e.g., 
for psoriasis or rheumatoid arthritis) include tacrolimus 
together with an antiproliferative agent, such as 
methotrexate, cyclophosphamide or the purine bio-
synthesis inhibitor mycophenolate mofetil, a prodrug 
of mycophenolic acid. 
CONCLUSIONS 
Although it is too early to draw firm conclusions 
about the value of tacrolimus in human autoimmune 
disease from the limited clinical investigations which 
have been undertaken to date, preliminary observa-
tions are encouraging. There is no doubt that tacroli-
mus is at least as efficacious an immunosuppressant 
as CsA. Its capacity (unlike CsA) to reverse allograft 
rejection suggests that it may be more broadly effec-
tive than CsA in autoimmune disease and may be 
useful in patients unresponsive to high dose steroids 
andlor other forms of immunosuppressive therapy. 
Further studies must include dose range and long term 
evaluation of tacrolimus therapy. Because tacrolimus 
augments hepatic repair and regeneration, it may prove 
especially valuable in patients with autoimmune liver 
disease. Although tacrolimus and CsA share several 
potential side effects, including nephrotoxicity, tac-
rolimus is less apt to induce hypertension and does 
not cause gingival hyperplasia or hirsutism at all. 
Amongst the beneficiaries of tacrolimus therapy have 
been children with nephrotic syndrome, in which prior 
high dose steroids have been discontinued. The in-
clusion of tacrolimus on the limited list of immuno-
suppressive drugs available for use in selected human 
autoimmune diseases appears justifiable. 
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